Avient’s Return On Capital Employed Overview

According to Benzinga Pro, during Q2, Avient (NYSE:AVNT) earned $84.70 million, a 0.24% increase from the preceding quarter. Avient also posted a total of $1.30 billion in sales, a 0.62% increase since Q1.

According to Benzinga Pro, during Q2, Avient (NYSE:AVNT) earned $84.70 million, a 0.24% increase from the preceding quarter. Avient also posted a total of $1.30 billion in sales, a 0.62% increase since Q1. Avient earned $84.50 million, and sales totaled $1.29 billion in Q1.

What Is Return On Capital Employed?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company’s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Avient posted an ROCE of 0.05%.

Keep in mind, while ROCE is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Avient is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Avient, the positive return on capital employed ratio of 0.05% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Upcoming Earnings Estimate

Avient reported Q2 earnings per share at $0.98/share, which beat analyst predictions of $0.92/share.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Cannabis Co. Entourage Health Reports 126% YoY Increase In 2023 Gross Profit, Cuts Losses Significantly

Canadian cannabis producer and distributor Entourage Health Corp., announced on Tuesday its financial results for the fiscal year that ended Dec. 31, 2023. The Toronto-based company reported a total net revenue of CA$40.7 million ($29.8 million) in 2023, slightly down from CA$40.9 million in 2022. However, gross profit before fair value changes reached CA$2.4 million in the same period, representing a 126% year-over-year increase. "In 2023, Entourage made significant strides, advancing production and diversifying our market presence with innovative products," George Scorsis, CEO and executive chair, said. "Dime Bag's success is a prime example—quickly rising to become one of Ontario's fastest-growing pre-roll brands and maintaining its market leadership for two consecutive quarters. Driven by surging demand for our products and the effectiveness of our enhanced business model, we're achieving growth while improving cost efficiency, firmly establishing ourselves in a favorable financial position."

ETRGF